Research / TCBX / Fundamental state Inspectable configuration
State dimensions Filing 0000950170-25-103125 Bank
Sequential deposit growth 14th Own-history percentile · N=14
Evidence method Sequential · gp.financial.deposits
0.76% · CORE · VALID
Net-income growth 45th Own-history percentile · N=11
Evidence method Yoy · gp.fundamentals.net_income
55.12% · CORE · VALID
Cash and equivalents 0th Own-history percentile · N=15
Evidence method Level · gp.fundamentals.cash
$113.1M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 19 states Self-history eligible
Dec 31, 2021 0/3 normalized Level 3 Mar 31, 2022 0/3 normalized Level 3 Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 0/5 normalized Level 3 Dec 31, 2022 0/5 normalized Level 3 Mar 31, 2023 0/5 normalized Level 3 Jun 30, 2023 0/5 normalized Level 3 Sep 30, 2023 1/5 normalized Level 3 Dec 31, 2023 3/5 normalized Level 3 Mar 31, 2024 3/5 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 3/3 normalized Level 3 Dec 31, 2024 3/3 normalized Level 3 Mar 31, 2025 3/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 4 Period transition
What moved in the state? Deposit Growth Increased
Previous -1.44%
Current 0.76%
Delta 2.20% Earnings Growth Increased
Previous 31.08%
Current 55.12%
Delta 24.04% Liquidity Decreased
Previous $219.0M
Current $113.1M
Delta -$105.8M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.